Reports Q3 revenue $17.63M, consensus $18.85M. Claude Maraoui, Journey Medical’s (DERM) co-founder, president and CEO, said, “Our third quarter 2025 results reflect continued strong execution and accelerating commercial momentum, with revenue increasing 21% year-over-year to $17.6 million. Emrosi(TM) continues to drive growth, generating $4.9 million in net sales in the third quarter alone, supported by robust market adoption and payer access that continues to expand. We anticipate the growth of Emrosi and our established dermatology commercial infrastructure to generate significant operating leverage going forward.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DERM: